Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its price objective upped by Mizuho from $145.00 to $179.00 in a research note published on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company's stock.

SRPT has been the subject of a number of other reports. TheStreet upgraded shares of Sarepta Therapeutics from a d rating to a c- rating in a report on Monday, March 4th. Evercore ISI raised their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an in-line rating in a research note on Tuesday, February 20th. UBS Group boosted their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a buy rating in a research report on Friday, March 1st. Oppenheimer upgraded Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 price target for the company in a research report on Tuesday. Finally, Needham & Company LLC reissued a buy rating and issued a $166.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $163.94.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $1.36 during midday trading on Friday, reaching $131.38. The stock had a trading volume of 848,974 shares, compared to its average volume of 1,025,304. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The company has a market capitalization of $12.42 billion, a P/E ratio of 1,194.36 and a beta of 0.95. The firm's 50 day moving average price is $126.50 and its 200-day moving average price is $112.30. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $152.21.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million for the quarter, compared to analysts' expectations of $375.52 million. During the same period in the previous year, the business earned ($1.44) earnings per share. Sarepta Therapeutics's revenue for the quarter was up 63.1% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics will post 2.68 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Dallan Murray sold 3,635 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Dallan Murray sold 3,635 shares of the business's stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company's stock, valued at approximately $2,537,500. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold a total of 25,731 shares of company stock worth $3,248,319 in the last ninety days. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the business. Capital International Investors raised its holdings in Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company's stock valued at $457,221,000 after buying an additional 2,917,797 shares in the last quarter. Norges Bank acquired a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $80,697,000. Bank of Nova Scotia bought a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $50,990,000. Avoro Capital Advisors LLC grew its holdings in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company's stock valued at $418,935,000 after purchasing an additional 319,444 shares during the last quarter. Finally, Mizuho Markets Americas LLC bought a new position in shares of Sarepta Therapeutics in the third quarter valued at approximately $29,813,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.